GeoVax Labs (GOVX) POS AM 20 Mar 15 2014 FY Prospectus update (post-effective amendment) Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 20, 2015	Jun. 30, 2014
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	832489
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		31,950,813
Entity Public Float			$4,780,857
Document Type	POS AM
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$1,101,651	$2,513,861
Grant funds receivable	79,341	140,909
Prepaid expenses and other current assets	44,503	43,569
Total current assets	1,225,495	2,698,339
Property and equipment, net	96,693	120,227
Other assets	11,010	21,010
Total assets	1,333,198	2,839,576
Current liabilities:
Accounts payable	55,616	155,943
Accrued expenses	52,490	96,406
Amounts payable to Emory University (a related party) (Note 12)	78,917	60,000
Total current liabilities	187,023	312,349
Commitments (Note 6)
Stockholders’ equity:
Initial carrying value of preferred stock	76,095	1,255,569
Issued and outstanding shares – 31,950,813 and 23,765,180 at December 31, 2014 and 2013, respectively	31,951	23,765
Additional paid-in capital	30,823,769	28,239,392
Accumulated deficit	-29,785,640	-27,052,085
Total stockholders’ equity	1,146,175	2,527,227
Total liabilities and stockholders’ equity	1,333,198	2,839,576
Series A Convertible Preferred Stock [Member]
Stockholders’ equity:
Initial carrying value of preferred stock	$0	$60,586

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	31,950,813	23,765,180
Common stock, shares outstanding (in shares)	31,950,813	23,765,180
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$1,000	$1,000
Preferred stock, shares issued (in shares)	0	71
Preferred stock, shares outstanding (in shares)	0	71
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$1,000	$1,000
Preferred stock, shares issued (in shares)	100	1,650
Preferred stock, shares outstanding (in shares)	100	1,650

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Grant revenue	$882,956	$2,417,550	$2,657,327
Operating expenses:
Research and development	1,812,969	2,914,878	3,043,522
General and administrative	1,807,605	1,792,160	1,752,765
Total operating expenses	3,620,574	4,707,038	4,796,287
Loss from operations	-2,737,618	-2,289,488	-2,138,960
Other income:
Interest income	4,063	4,545	3,820
Total other income	4,063	4,545	3,820
Net loss	($2,733,555)	($2,284,943)	($2,135,140)
Basic and diluted:
Loss per common share (in dollars per share)	($0.10)	($0.11)	($0.12)
Weighted average shares outstanding (in shares)	26,645,140	21,212,327	18,315,669

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Accumulated Deficit during Development Stage [Member]	Additional Paid-in Capital [Member]	Common Stock [Member]	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]
Balance at December 31, 2011 at Dec. 31, 2011	$703,607	($22,632,002)	$23,319,166	$16,443
Balance at December 31, 2011 (in shares) at Dec. 31, 2011				16,442,611
Sale of common stock for cash (in shares)				407,999
Sale of common stock for cash	273,360		272,952	408
Sale of convertible preferred stock and warrants for cash (in shares)					2,200
Sale of convertible preferred stock and warrants for cash	1,999,032		1,127,418		871,614
Conversion of preferred stock (in shares)				1,882,667	-1,412
Conversion of preferred stock to common stock			557,536	1,882	-559,418
Stock-based compensation expense	310,076		310,076
Net loss	-2,135,140	-2,135,140
Balance at December 31, 2012 at Dec. 31, 2012	1,150,935	-24,767,142	25,587,148	18,733	312,196
Balance at December 31, 2012 (in shares) at Dec. 31, 2012				18,733,277	788
Sale of convertible preferred stock and warrants for cash (in shares)						1,650
Sale of convertible preferred stock and warrants for cash	1,615,798				360,229	1,255,569
Conversion of preferred stock (in shares)				2,048,570	-717
Conversion of preferred stock to common stock			609,790	2,049	-611,839
Stock-based compensation expense	381,604		381,604
Net loss	-2,284,943	-2,284,943
Sale of common stock for cash upon warrant exercise (in shares)				2,933,333
Sale of common stock for cash upon warrant exercise	1,643,333		1,640,400	2,933
Issuance of common stock for services (in shares)				50,000
Issuance of common stock for services	20,500		20,450	50
Balance at December 31, 2012 at Dec. 31, 2013	2,527,227	-27,052,085	28,239,392	23,765	60,586	1,255,569
Balance at December 31, 2012 (in shares) at Dec. 31, 2013				23,765,180	71	1,650
Conversion of preferred stock (in shares)				4,631,428	-71	-1,550
Conversion of preferred stock to common stock			1,235,428	4,632	-60,586	-1,179,474
Stock-based compensation expense	379,103		379,103
Net loss	-2,733,555	-2,733,555
Sale of common stock for cash upon warrant exercise (in shares)				3,176,000
Sale of common stock for cash upon warrant exercise	873,400		870,224	3,176
Issuance of common stock for services (in shares)				378,205
Issuance of common stock for services	100,000		99,622	378
Balance at December 31, 2012 at Dec. 31, 2014	$1,146,175	($29,785,640)	$30,823,769	$31,951		$76,095
Balance at December 31, 2012 (in shares) at Dec. 31, 2014				31,950,813		100

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	($2,733,555)	($2,284,943)	($2,135,140)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	69,037	78,862	93,643
Stock-based compensation expense, including common stock issued for services	479,103	402,104	310,076
Changes in assets and liabilities:
Grant funds receivable	61,568	125,339	-82,733
Prepaid expenses and other current assets	-934	-1,268	-12,593
Accounts payable and accrued expenses	-125,326	-14,686	-614,500
Total adjustments	483,448	590,351	-306,107
Net cash used in operating activities	-2,250,107	-1,694,592	-2,441,247
Cash flows from investing activities:
Purchase of property and equipment	-35,503	-86,603
Net cash used in investing activities	-35,503	-86,603
Cash flows from financing activities:
Proceeds from sale of common stock	873,400	1,643,333	310,160
Proceeds from sale of preferred stock		1,615,798	1,999,032
Net cash provided in financing activities	873,400	3,259,131	2,309,192
Net increase (decrease) in cash and cash equivalents	-1,412,210	1,477,936	-132,055
Cash and cash equivalents at beginning of period	2,513,861	1,035,925	1,167,980
Cash and cash equivalents at end of period	$1,101,651	$2,513,861	$1,035,925

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parentheticals)	1 Months Ended	12 Months Ended
	Jan. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Series A Convertible Preferred Stock [Member]
Convertible preferred stock (in shares)	71	71	717	1,412
Common stock conversion (in shares)	202,857	202,857	2,048,570	1,882,667
Series B Convertible Preferred Stock [Member]
Convertible preferred stock (in shares)		1,550
Common stock conversion (in shares)		4,428,571	0	0

Note_1_Description_of_Business

Note 1 - Description of Business	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Nature of Operations [Text Block]	1	Description
		of Business
	GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing innovative human vaccines using our novel DNA/MVA platform technology. Our lead programs are focused on Ebola virus and Human Immunodeficiency Virus (HIV). Our vaccine delivery technology generates virus-like particles (VLPs) that are effective at eliciting safe and effective immune responses. All of the clinical trials for our preventive HIV vaccine have been conducted by the HIV Vaccine Trials Network (HVTN) with funding from the National Institutes of Health (NIH). Our proprietary Ebola vaccine technology has been developed internally, while our HIV vaccine technology was developed in collaboration with Emory University, the NIH, and the
	Centers for Disease Control and Prevention (CDC) and is exclusively licensed to us.
	Our most advanced vaccines under development address the clade B subtype of the HIV virus that is most prevalent in the developed world – primarily North America and Western Europe. Our preventive clade B HIV vaccine has successfully completed Phase 2a clinical trials and we are currently planning the next stage of human clinical testing. We are also planning clinical trials to evaluate our clade B HIV vaccine as an immunotherapy agent for individuals already infected with HIV. We have begun early-stage preclinical studies to develop HIV vaccine candidates for the clade C subtype of HIV prevalent in the developing world. Our Ebola vaccine development efforts were initiated in 2014 and we expect to conduct preclinical animal studies during 2015, with the goal of beginning human clinical testing in 2016.
	We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain and may take many years and may involve expenditure of substantial resources. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with one or more potential strategic partners.
	GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2	Summary of Significant Accounting Policies
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development. We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue these activities. We believe that our existing cash resources, combined with the proceeds from the NIH grants discussed in Note 5 and the net proceeds of the financing transaction discussed in Note 14, will be sufficient to fund our planned operations through the first quarter of 2016.
	We expect we will need to raise additional funds to significantly advance our vaccine development programs and we are currently exploring sources of non-dilutive capital through government grant programs and clinical trial support. However, additional funding may not be available on favorable terms or at all. If we fail to obtain additional capital when needed, we may be required to delay, scale back, or eliminate some or all of our research and development programs as well as reduce our general and administrative expenses.
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2014-15,
	Presentation of Financial Statements – Going Concern
	(“ASU 2014-15”), which requires management of all entities to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued, and to make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 is effective for the Company for annual reporting periods beginning in 2016 and for interim reporting periods starting in the first quarter of 2017. We are currently evaluating the impact of the adoption of ASU 2014-15 on our financial statements.
	Development-Stage Enterprise
	In June 2014, the FASB issued Accounting Standards Update 2014-10,
	Development Stage Entities (Topic 915)
	("ASU 2014-10")
	.
	The amendments in ASU 2014-10 remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. generally accepted accounting principles (“GAAP”). In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder’s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. We have evaluated this accounting standard and determined it to have a material impact on our financial statements. We adopted ASU-2014-10 effective June 30, 2014 and the effects of the adoption are reflected in our consolidated financial statements and footnotes contained herein.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.
	Cash and Cash Equivalents
	We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.
	Fair Value of Financial Instruments and Concentration of Credit Risk
	Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.
	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three to five years. We amortize leasehold improvements using the straight-line method over the term of the related lease.
	Impairment of Long-Lived Assets
	We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be
	recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.
	Accrued Liabilities
	As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not yet been billed by our third party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.
	Net Loss Per Share
	Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 6.6 million, 14.4 million, and 13.3 million at December 31, 2014, 2013 and 2012, respectively.
	Revenue Recognition
	We recognize revenue in accordance with U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 101,
	Revenue Recognition in Financial Statements,
	as amended by Staff Accounting Bulletin No. 104,
	Revenue Recognition,
	(“SAB 104”). SAB 104 provides guidance in applying GAAP to revenue recognition issues, and specifically addresses revenue recognition for upfront, nonrefundable fees received in connection with research collaboration agreements. During 2014, 2013 and 2012, our revenue consisted of grant funding received from the NIH (see Note 5). Revenue from these arrangements is approximately equal to the costs incurred and is recorded as income as the related costs are incurred.
	In May 2014, the FASB issued Accounting Standards Update 2014-09,
	Revenue from Contracts with Customers
	(“ASU 2014-09”), which creates a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for the Company beginning in 2017 and allows for either full retrospective adoption or modified retrospective adoption. We are currently evaluating the impact of the adoption of ASU 2014-09 on our financial statements.
	Research and Development Expense
	Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) fees paid to third-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (ii) costs related to sponsored research agreements, (iii) the costs to procure and manufacture materials used in clinical trials, (iv) laboratory supplies and facility-related expenses to conduct development, and (v) salaries, benefits, and stock-based compensation for personnel. These costs are charged to expense as incurred.
	Patent Costs
	Our expenditures relating to obtaining and protecting patents are charged to expense when incurred, and are included in general and administrative expense.
	Period to Period Comparisons
	Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results for future periods.
	Income Taxes
	We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized.
	Stock-Based Compensation
	We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 9 for additional stock-based compensation information.
	Recent Accounting Pronouncements
	Except as discussed above, there have been no recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on our financial statements.

Note_3_Property_and_Equipment

Note 3 - Property and Equipment	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	3	Property and Equipment
	Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2014 and 2013:
			2014			2013
	Laboratory equipment		$	510,106		$	474,602
	Leasehold improvements			115,605			115,605
	Other furniture, fixtures & equipment			28,685			28,685
	Total property and equipment			654,396			618,892
	Accumulated depreciation and amortization			(557,703	)		(498,665	)
	Property and equipment, net		$	96,693		$	120,227
	Depreciation and amortization expense was $59,037, $68,862, and $73,720 during the years ended December 31, 2014, 2013 and 2012, respectively.

Note_4_Other_Assets

Note 4 - Other Assets	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Other Assets Disclosure [Text Block]	4	Other Assets
	Other assets as shown on the accompanying Consolidated Balance Sheets include the following as of December 31, 2014 and 2013:
			2014			2013
	Technology licenses		$	248,855		$	248,855
	Deposits			11,010			11,010
	Accumulated amortization – technology licenses			(248,855	)		(238,855	)
	Total other assets		$	11,010		$	21,010
	Amortization expense related to technology licenses was $10,000, $10,000, and $19,923 during the years ended December 31, 2014, 2013 and 2012, respectively.

Note_5_Government_Grants

Note 5 - Government Grants	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Government Grants [Text Block]	5	Government Grants
	.
	We record revenue associated with government grants as the related costs and expenses are incurred and such revenue is reported as a separate line item in our statements of operations. Grant revenues relate to grants from the NIH in support of our HIV vaccine development activities. During 2014, 2013, and 2012, we recorded $882,956, $2,417,550, and $2,657,327, respectively, of revenue associated with these grants. Additional detail concerning our grant revenues is discussed below.
	In September 2007, the NIH awarded us a grant entitled “GM-CSF-Adjuvanted Clade C DNA/MVA and MVA/MVA Vaccines”. The aggregate award (including subsequent amendments) totaled approximately $20.4 million. We recorded grant revenues of $624,689, $833,390, and $2,227,924 for the years ended December 31, 2014, 2013 and 2012, respectively, related to this grant, and there is $75,464 of unrecognized grant funds remaining and available for use pursuant to this grant as of December 31, 2014.
	In September 2012, the NIH awarded us a grant entitled “Immunogens and Manufacturing” to support our HIV/AIDS vaccine development program. The grant award was for approximately $1.9 million. We recorded grant revenues of $-0-, $1,429,597, and $429,403 for the years ended December 31, 2014, 2013 and 2012, respectively, related to this grant, and all funding pursuant to this grant has been utilized as of December 31, 2014.
	In July 2013, the NIH awarded us a Small Business Innovative Research (SBIR) grant entitled “Enhancing Protective Antibody Responses for a GM-CSF Adjuvanted HIV Vaccine.” The initial grant award was $276,690 for the first year of a two year project period beginning August 1, 2013. In July 2014, the NIH awarded us $289,641 for the second year of the project period. We recorded grant revenues of $258,267, $154,563, and $-0- for the years ended December 31, 2014, 2013 and 2012, respectively, related to this grant, and there is $153,501 of unrecognized grant funds remaining and available for use pursuant to this grant as of December 31, 2014.

Note_6_Commitments

Note 6 - Commitments	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Commitments Disclosure [Text Block]	6	Commitments
	.
	Lease Agreements
	We lease approximately 8,400 square feet of office and laboratory space located in Smyrna, Georgia (metropolitan Atlanta). Rent expense for the years ended December 31, 2014, 2013 and 2012 was $117,084, $117,879, and $118,801, respectively. The original 62-month lease term expired on December 31, 2014 and we have renewed the lease for an additional 12 months, with two successive 12-month renewal options. Future minimum lease payments total $146,092 in 2015.
	Other Commitments
	In the normal course of business, we may enter into various firm purchase commitments related to production and testing of our vaccine material, conduct of clinical trials, and other research-related activities. As of December 31, 2014, we had approximately $151,439 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in 2015.

Note_7_Preferred_Stock

Note 7 - Preferred Stock	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Preferred Stock [Text Block]	7	Preferred Stock
	.
	Series A Convertible Preferred Stock
	In March 2012, we issued 2,200 shares of our Series A Convertible Preferred Stock, $1,000 stated value (“Series A Preferred Stock”), which were originally convertible into 2,933,333 shares of our common stock, and warrants to purchase up to 8,799,999 shares of our common stock for gross proceeds of $2.2 million. Net proceeds, after deduction of placement agent fees and other expenses, were approximately $2.0 million.
	Each share of Series A Preferred Stock was entitled to a liquidation preference equal to the initial purchase price, had no voting rights, and was not entitled to a dividend. The Series A Preferred Stock was convertible at any time at the option of the holders into shares of our common stock. The initial conversion price was $0.75 and during 2012, 1,412 of the Series A Preferred Shares were converted at this price into an aggregate of 1,882,667 shares of our common stock. Effective December 11, 2013, we amended the designation of the Series A Preferred Stock in connection with the issuance of our Series B Convertible Preferred Stock (see discussion below). The amendment had the effect of reducing the conversion price of the then-outstanding Series A Preferred Stock to $0.35 and during the remainder of 2013, 717 shares of the Series A Preferred Stock were converted at this price into an aggregate of 2,048,570 shares of our common stock. The remaining 71 shares of Series A Preferred Stock were converted into 202,857 shares of our common stock in January 2014, and there are no shares of Series A Preferred Stock outstanding at December 31, 2014.
	We assessed the Series A Preferred Stock and the related warrants under ASC Topic 480, “
	Distinguishing Liabilities from Equity
	” (“ASC 480”), ASC Topic 815, “
	Derivatives and Hedging
	” (“ASC 815”), and ASC Topic 470, “
	Debt
	” (“ASC 470”). The preferred stock contains an embedded feature allowing an optional conversion by the holder into common stock which meets the definition of a derivative. However, we determined that the preferred stock is an “equity host” (as described by ASC 815) for purposes of assessing the embedded derivative for potential bifurcation and that the optional conversion feature is clearly and closely associated to the preferred stock host; therefore the embedded derivative does not require bifurcation and separate recognition under ASC 815. We determined there to be a beneficial conversion feature (“BCF”) requiring recognition at its intrinsic value. Since the conversion option of the preferred stock was immediately exercisable, the amount allocated to the BCF was immediately accreted to preferred dividends, resulting in an increase in the carrying value of the preferred stock. We also assessed the warrants issued in connection with the financing under ASC 815 and determined that they did not initially meet the definition of a derivative, but will require evaluation on an on-going basis. As of December 31, 2014, we determined that the warrants still did not meet the definition of a derivative.
	The following is a summary of the allocation of net proceeds and reconciliation to the carrying value of the Series A Preferred Stock at December 31, 2014:
	Net proceeds		$	1,999,032
	Fair value of warrants (recorded to Additional Paid-in Capital)			(1,127,418	)
	Beneficial conversion feature (recorded to Additional Paid-in Capital)			(762,667	)
	Net proceeds allocated to preferred stock			108,947
	Accretion of beneficial conversion feature (deemed dividend)			762,667
	Initial carrying value of preferred stock			871,614
	Accretion of beneficial conversion feature (deemed dividend) related to issuance			360,229
	of Series B Convertible Preferred Stock
	Conversions to common stock			(1,231,843	)
	Carrying value at December 31, 2014		$	0	-
	Series B Convertible Preferred Stock
	In December 2013, we issued 1,650 shares of our Series B Convertible Preferred Stock, $1,000 stated value (“Series B Preferred Stock”), which was originally convertible into 4,714,286 shares of our common stock, for gross proceeds of $1.65 million. Net proceeds, after deduction of transaction expenses, were approximately $1.6 million. No warrants were issued in connection with the transaction.
	Each share of Series B Preferred Stock has a liquidation preference equal to the initial purchase price, has no voting rights, and is not entitled to a dividend. The Series B Preferred Stock may be converted at any time at the option of the holders into shares of our common stock at a conversion price of $0.35. During 2014, 1,550 shares of the Series B Preferred Stock were converted into 4,428,571 shares of our common stock. As of December 31, 2014, there were 100 shares of Series B Preferred Stock outstanding, convertible into 285,714 shares of our common stock.
	In conjunction with the issuance of the Series B Preferred Stock, we entered into an agreement with the holders of the Series A Preferred Stock to amend the designation of the Series A Preferred Stock. The amendment had the effect of reducing the conversion price of the then-outstanding 788 Series A Preferred Shares from $0.75 to $0.35.
	We assessed the Series B Preferred Stock using the same methodology as for the Series A Preferred Stock (see discussion above), and resulting in the same determinations. The following is a summary of the allocation of net proceeds and reconciliation to the carrying value of the Series B Preferred Stock at December 31, 2014:
	Net proceeds		$	1,615,798
	Beneficial conversion feature – Series A Preferred Stock (recorded to Additional Paid-in Capital)			(360,229	)
	Beneficial conversion feature – Series B Preferred Stock (recorded to Additional Paid-in Capital)			(754,286	)
	Net proceeds allocated to preferred stock			501,283
	Accretion of beneficial conversion feature (deemed dividend)			754,286
	Conversions to common stock			(1,179,474	)
	Carrying value at December 31, 2014		$	76,095

Note_8_Common_Stock

Note 8 - Common Stock	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8	Common Stock
	Common Stock Transactions
	During December 2011 and January 2012, we sold an aggregate of 1,066,519 of our common stock to a group of individual accredited investors (including members of our board of directors and management --see Note 12) for an aggregate purchase price of $714,570. We also issued to the investors five-year warrants to purchase an aggregate of 1,599,784 shares of common stock at a price of $1.00 per share.
	During January and May 2013, we issued an aggregate of 2,933,333 shares of our common stock pursuant to the exercise of certain stock purchase warrants, resulting in total net proceeds of $1,643,333 (see “
	Stock Purchase Warrants
	” below).
	During October 2013, we issued 50,000 shares of our common stock to a consultant in exchange for services and recorded general and administrative expense of $20,500 related to the issuance (see Note 9 – “
	Other Non-Employee Stock-Based Compensation Expense
	”
	).
	During July and November 2014, we issued an aggregate of 378,205 shares of our common stock to a consultant in exchange for services and recorded aggregate general and administrative expense of $100,000 related to the issuances (see see Note 9 – “
	Other Non-Employee Stock-Based Compensation Expense
	”
	).
	During October 2014, we issued an aggregate of 3,176,000 shares of our common stock pursuant to the exercise of certain stock purchase warrants, resulting in total net proceeds of $873,400 (see “
	Stock Purchase Warrants
	” below).
	During 2014, 2013 and 2012, we issued shares of our common stock related to conversions of our Series A and Series B Preferred Stock (see Note 7) as follows:
			2014		2013		2012
	Conversion of Series A Preferred Shares			202,857		2,048,570		1,882,667
	Conversion of Series B Preferred Shares			4,428,571		-0-		-0-
	Stock Purchase
	Warrants
	As of December 31, 2014, we have the following stock purchase warrants outstanding:
	Expiration Date		Number of Shares		Weighted Average
					Exercise Price
	31-Dec-16			1,806,159	$	1
	16-Jan-17			45,000		1
	31-Jan-17			567,001		1
	21-Mar-17			2,690,666		0.35
	Total Outstanding at December 31, 2014			5,108,826	$	0.66
	During January 2013, we reduced the exercise price of warrants to purchase 2,933,333 shares of our common stock from $0.75 to $0.60 per share. In consideration for the reduction of the exercise price, the holders of the warrants immediately exercised 1,766,667 of the warrants for cash, resulting in total proceeds to the Company of $1,060,000. We also extended the expiration date of the 1,166,666 unexercised warrants from March 21, 2013 to May 21, 2013. We recorded general and administrative expense of $218,551 associated with these warrant modifications. During May 2013, we reduced the exercise price of the 1,166,666 remaining warrants from $0.60 to $0.50 per share. In consideration for the reduction of the exercise price, the holders of the warrants immediately exercised all of the remaining warrants for cash, resulting in total proceeds to the Company of $583,333. We recorded general and administrative expense of $19,617 associated with this warrant modification.
	During September 2014, we reduced the exercise price of warrants to purchase 818,376 shares of our common stock from $16.50 to $1.00 per share, and extended the expiration dates from December 31, 2014 to December 31, 2016. We recorded general and administrative expense of $39,711 associated with these modifications.
	During October 2014, we entered into an agreement with certain holders of warrants to purchase shares of our common stock with respect to the payment to them of a warrant exercise fee of $0.075 per share for each share purchased upon exercise of warrants held by them. In exchange for the fee, they immediately exercised warrants for an aggregate of 3,176,000 shares of our common stock, resulting in proceeds to us of $873,400 (net of the exercise fee).
	Common Stock Reserved
	A summary of common stock reserved for future issuance as of December 31, 2014 is as follows:
	Stock Purchase Warrants			5,108,826
	Stock Option Plan			1,197,529
	Series B Convertible Preferred Stock			285,715
	Total			6,592,070

Note_9_StockBased_Compensation

Note 9 - Stock-Based Compensation	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9	Stock-Based Compensation
	Stock Option Plan
	In 2006, we adopted the GeoVax Labs, Inc. 2006 Equity Incentive Plan (the “Stock Option Plan”) for the granting of qualified incentive stock options (“ISO’s”), nonqualified stock options, restricted stock awards or restricted stock bonuses to employees, officers, directors, consultants and advisors of the Company. The exercise price for any option granted may not be less than fair value (110% of fair value for ISO’s granted to certain employees). Options granted under the Stock Option Plan have a maximum ten-year term and generally vest over three years. The Company has reserved 1,200,000 shares of its common stock for issuance under the Stock Option Plan.
	Certain information concerning the Stock Option Plan as of December 31, 2014, and a summary of activity during the year then ended is presented below:
			Number			Weighted-			Weighted-			Aggregate
			of Shares			Average			Average			Intrinsic
						Exercise			Remaining			Value
						Price			Contractual
									Term (yrs)
	Outstanding at December 31, 2013			1,197,044		$	3.79
	Granted			217,500			0.17
	Exercised			-			-
	Forfeited or expired			(231,444	)		1.89
	Outstanding at December 31, 2014			1,183,100		$	3.5			6.6		$	-0-
	Exercisable at December 31, 2014			785,594		$	5.09			5.2		$	-0-
	Additional information concerning our stock options for the years ended December 31, 2014, 2013 and 2012 is as follows:
			2014			2013			2012
	Weighted average fair value of options granted		$	0.14		$	0.43		$	0.59
	Intrinsic value of options exercised			-0-			-0-			-0-
	Total fair value of options vested			97,707			165,490			319,920
	We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows:
			2014			2013			2012
	Weighted average risk-free interest rates			1.98	%		2.3	%		1.1	%
	Expected dividend yield			0	%		0	%		0	%
	Expected life of option (years)			7			7			6.7
	Expected volatility			94.88	%		96.6	%		105.2	%
	Stock-based compensation expense related to the Stock Option Plan was $101,191, $143,435, and $310,076 during the years ended December 31, 2014, 2013 and 2012, respectively. Stock option expense is allocated to research and development expense or to general and administrative expense based on the nature of the services provided by the related individuals. For the three years ended December 31, 2014, stock option expense was allocated as follows:
			2014			2013			2012
	General and administrative expense		$	69,057		$	101,896		$	231,936
	Research and development expense			32,134			41,539			78,140
	Total stock option expense		$	101,191		$	143,435		$	310,076
	As of December 31, 2014, there was $110,235 of unrecognized compensation expense related to stock-based compensation arrangements pursuant to the Stock Option Plan. The unrecognized compensation expense is expected to be recognized over a weighted average remaining period of 1.9 years.
	Other Non-E
	mp
	loyee Stock-Based C
	ompensation
	We recorded general and administrative expense of $100,000, $20,500, and $-0- during the years ended December 31, 2014, 2013 and 2012, respectively, related to the issuance of our common stock in exchange for services rendered by non-employees (See Note 8 – “
	Common Stock Transactions
	”).
	We recorded general and administrative expense of $39,712, $238,168, and $-0- during the years ended December 31, 2014, 2013 and 2012, respectively, related to modifications made to certain stock purchase warrants (see Note 8 – “
	Stock Purchase Warrants
	”).
	During 2014, we recorded general and administrative expense of $238,200 related to a warrant exercise fee paid to certain holders of our stock purchase warrants as an incentive for the holders to immediately certain warrants (see Note 8 – “
	Stock Purchase Warrants
	”).
	As of December 31, 2014, there was no unrecognized expense related to any non-employee stock-based compensation arrangements.

Note_10_Retirement_Plan

Note 10 - Retirement Plan	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	10	Retirement Plan
	.
	We participate in a multi-employer defined contribution retirement plan (the “401k Plan”) administered by a third party service provider; and the Company contributes to the 401k Plan on behalf of its employees based upon a matching formula. During the years ended December 31, 2014, 2013 and 2012 our contributions to the 401k Plan were $35,567, $43,132, and $50,500, respectively.

Note_11_Income_Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11	Income Taxes
	.
	At December 31, 2014, we have a consolidated federal net operating loss (“NOL”) carryforward of approximately $64.6 million, available to offset against future taxable income which expires in varying amounts in 2019 through 2034. Additionally, we have approximately $826,000 in research and development (“R&D”) tax credits that expire in 2022 through 2034 unless utilized earlier. No income taxes have been paid to date.
	Section 382 of the Internal Revenue Code contains provisions that may limit our utilization of our NOL and R&D tax credit carryforwards in any given year as a result of significant changes in ownership interests that have occurred in past periods or may occur in future periods.
	F- 15
	Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at December 31, 2014 and 2013:
			2014			2013
	Deferred tax assets:
	Net operating loss carryforward		$	22,831,626		$	21,983,109
	Research and development tax credit carryforward			825,896			799,248
	Stock-based compensation expense			2,396,805			2,233,909
	Total deferred tax assets			26,054,327			25,016,266
	Deferred tax liabilities
	Depreciation			(7,149	)		(13,386	)
	Total deferred tax liabilities			(7,149	)		(13,386	)
	Net deferred tax assets			26,047,178			25,002,881
	Valuation allowance			(26,047,178	)		(25,002,881	)
			$	-0-		$	-0-
	We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future.
	A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows:
			2014			2013			2012
	U.S. federal statutory rate applied to pretax loss		$	(929,409	)	$	(776,881	)	$	(725,948	)
	Permanent differences			1,734			3,138			2,674
	Research and development credits			26,648			14,047			21,236
	Change in valuation allowance			901,027			759,696			702,038
	Reported income tax expense		$	-0-		$	-0-		$	-0-

Note_12_Related_Party_Transact

Note 12 - Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	12	Related Party Transactions
	.
	We are obligated to reimburse Emory University (a significant stockholder of the Company) for ongoing costs in connection with the filing, prosecution and maintenance of patent applications subject to a license agreement for technology associated with the vaccines we are developing. The expense associated with these ongoing patent cost reimbursements to Emory amounted to $179,958, $98,042, and $89,885 for the years ended December 31, 2014, 2013, and 2012, respectively.
	In connection with our IPCAVD grant from the NIH (see Note 5), we entered into subcontracts with Emory for the purpose of conducting research and development activities related to the grant. During 2014, 2013, and 2012, we recorded $-0-, $252,478 and $552,403, respectively, of expense associated with these subcontracts. All amounts paid to Emory under these subcontracts are reimbursable to us pursuant to the NIH grant.
	In December 2011 and January 2012, members of our management and Board of Directors participated in a private placement offering of our common stock and warrants (see Note 8), whereby they purchased an aggregate of 380,954 shares of our common stock for a total purchase price of $255,239 and received five-year warrants to purchase an additional 571,432 shares of our common stock exercisable at $1.00 per share.

Note_13_Selected_Quarterly_Fin

Note 13 - Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Quarterly Financial Information [Text Block]	13	Selected Quarterly Financial Data (unaudited)
	.
	A summary of selected quarterly financial data for 2014 and 2013 is as follows:
			2014 Quarter Ended
			31-Mar			30-Jun			30-Sep			31-Dec
	Revenue from grants		$	157,340		$	180,441		$	322,086		$	223,089
	Net loss			(615,918	)		(679,537	)		(514,515	)		(923,585	)
	Net loss per share			(0.02	)		(0.03	)		(0.02	)		(0.03	)
			2013 Quarter Ended
			31-Mar			30-Jun			30-Sep			31-Dec
	Revenue from grants		$	797,040		$	441,561		$	1,004,211		$	174,738
	Net loss			(696,797	)		(526,284	)		(190,148	)		(871,714	)
	Net loss per share			(0.03	)		(0.02	)		(0.01	)		(0.04	)

Note_14_Subsequent_Event

Note 14 - Subsequent Event	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Subsequent Events [Text Block]	14	Subsequent Event
	.
	On February 27, 2015, we sold shares of our Series C convertible preferred stock to certain institutional investors for an aggregate purchase price of $3.0 million. The preferred stock is convertible at any time into shares of our common stock at $0.18 per share (16,666,666 shares in the aggregate), subject to possible adjustment as provided in the certificate of designation.
	Pursuant to the terms of the securities purchase agreement, the investors also received five-year Series D warrants to purchase an aggregate of 16,666,666 shares of our common stock at $0.22 per share. The Series D warrants are immediately exercisable. We also granted to the investors a one-year additional purchase right, evidenced in the form of Series E warrants, to purchase up to 16,666,666 of our common stock for one year with an exercise price of $0.18 per share, and five-year Series F warrants to purchase up to 16,666,666 shares of our common stock at $0.22 per share. The Series D warrants are immediately exercisable. The Series F warrants only vest and become exercisable at the time, and to the extent, that the Series E warrants are exercised. The placement agent for the offering was granted a Series D warrants (exercisable immediately) to purchase 1,333,333 shares of our common stock at $0.22 per share.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	GEOVAX LABS, INC.
	SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS
	For t
	he Years Ended December 31, 2014, 2013 and 2012
					Additions
	Description		Balance at		Charged to		Charged to		-1			Balance at
			Beginning		Costs and		Other		Deductions			End
			Of Period		Expenses		Accounts					Of Period
	Reserve Deducted in the Balance Sheet
	From the Asset to Which it Applies:
	Allowance for Deferred Tax Assets
	Year ended December 31, 2014		$	25,002,881	$	1,044,297	$	-0-	$	-0-		$	26,047,178
	Year ended December 31, 2013			27,295,741		862,736		-0-	$	(3,155,596	)		25,002,881
	Year ended December 31, 2012			27,591,230		817,472		-0-		(1,112,961	)		27,295,741
		-1	Deductions represent the effect of expiring NOL carryforwards from prior year.

Significant_Accounting_Policie

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
	The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development. We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue these activities. We believe that our existing cash resources, combined with the proceeds from the NIH grants discussed in Note 5 and the net proceeds of the financing transaction discussed in Note 14, will be sufficient to fund our planned operations through the first quarter of 2016.
	We expect we will need to raise additional funds to significantly advance our vaccine development programs and we are currently exploring sources of non-dilutive capital through government grant programs and clinical trial support. However, additional funding may not be available on favorable terms or at all. If we fail to obtain additional capital when needed, we may be required to delay, scale back, or eliminate some or all of our research and development programs as well as reduce our general and administrative expenses.
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2014-15,
	Presentation of Financial Statements – Going Concern
	(“ASU 2014-15”), which requires management of all entities to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued, and to make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 is effective for the Company for annual reporting periods beginning in 2016 and for interim reporting periods starting in the first quarter of 2017. We are currently evaluating the impact of the adoption of ASU 2014-15 on our financial statements.
Development Stage Enterprise [Policy Text Block]	Development-Stage Enterprise
	In June 2014, the FASB issued Accounting Standards Update 2014-10,
	Development Stage Entities (Topic 915)
	("ASU 2014-10")
	.
	The amendments in ASU 2014-10 remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. generally accepted accounting principles (“GAAP”). In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder’s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. We have evaluated this accounting standard and determined it to have a material impact on our financial statements. We adopted ASU-2014-10 effective June 30, 2014 and the effects of the adoption are reflected in our consolidated financial statements and footnotes contained herein.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments and Concentration of Credit Risk
	Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three to five years. We amortize leasehold improvements using the straight-line method over the term of the related lease.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets
	We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be
	recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.
Accrued Liabilities [Policy Text Block]	Accrued Liabilities
	As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not yet been billed by our third party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share
	Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 6.6 million, 14.4 million, and 13.3 million at December 31, 2014, 2013 and 2012, respectively.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	We recognize revenue in accordance with U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 101,
	Revenue Recognition in Financial Statements,
	as amended by Staff Accounting Bulletin No. 104,
	Revenue Recognition,
	(“SAB 104”). SAB 104 provides guidance in applying GAAP to revenue recognition issues, and specifically addresses revenue recognition for upfront, nonrefundable fees received in connection with research collaboration agreements. During 2014, 2013 and 2012, our revenue consisted of grant funding received from the NIH (see Note 5). Revenue from these arrangements is approximately equal to the costs incurred and is recorded as income as the related costs are incurred.
	In May 2014, the FASB issued Accounting Standards Update 2014-09,
	Revenue from Contracts with Customers
	(“ASU 2014-09”), which creates a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for the Company beginning in 2017 and allows for either full retrospective adoption or modified retrospective adoption. We are currently evaluating the impact of the adoption of ASU 2014-09 on our financial statements.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense
	Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) fees paid to third-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (ii) costs related to sponsored research agreements, (iii) the costs to procure and manufacture materials used in clinical trials, (iv) laboratory supplies and facility-related expenses to conduct development, and (v) salaries, benefits, and stock-based compensation for personnel. These costs are charged to expense as incurred.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patent Costs
	Our expenditures relating to obtaining and protecting patents are charged to expense when incurred, and are included in general and administrative expense.
Reclassification, Policy [Policy Text Block]	Period to Period Comparisons
	Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results for future periods.
Income Tax, Policy [Policy Text Block]	Income Taxes
	We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation
	We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 9 for additional stock-based compensation information.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	Except as discussed above, there have been no recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on our financial statements.

Note_3_Property_and_Equipment_

Note 3 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Property, Plant and Equipment [Table Text Block]		2014			2013
	Laboratory equipment	$	510,106		$	474,602
	Leasehold improvements		115,605			115,605
	Other furniture, fixtures & equipment		28,685			28,685
	Total property and equipment		654,396			618,892
	Accumulated depreciation and amortization		(557,703	)		(498,665	)
	Property and equipment, net	$	96,693		$	120,227

Note_4_Other_Assets_Tables

Note 4 - Other Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Schedule of Other Assets [Table Text Block]		2014			2013
	Technology licenses	$	248,855		$	248,855
	Deposits		11,010			11,010
	Accumulated amortization – technology licenses		(248,855	)		(238,855	)
	Total other assets	$	11,010		$	21,010

Note_7_Preferred_Stock_Tables

Note 7 - Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Allocation Of Net Proceeds From Preferred Stock Financing [Table Text Block]	Net proceeds	$	1,999,032
	Fair value of warrants (recorded to Additional Paid-in Capital)		(1,127,418	)
	Beneficial conversion feature (recorded to Additional Paid-in Capital)		(762,667	)
	Net proceeds allocated to preferred stock		108,947
	Accretion of beneficial conversion feature (deemed dividend)		762,667
	Initial carrying value of preferred stock		871,614
	Accretion of beneficial conversion feature (deemed dividend) related to issuance		360,229
	of Series B Convertible Preferred Stock
	Conversions to common stock		(1,231,843	)
	Carrying value at December 31, 2014	$	0	-
	Net proceeds	$	1,615,798
	Beneficial conversion feature – Series A Preferred Stock (recorded to Additional Paid-in Capital)		(360,229	)
	Beneficial conversion feature – Series B Preferred Stock (recorded to Additional Paid-in Capital)		(754,286	)
	Net proceeds allocated to preferred stock		501,283
	Accretion of beneficial conversion feature (deemed dividend)		754,286
	Conversions to common stock		(1,179,474	)
	Carrying value at December 31, 2014	$	76,095

Note_8_Common_Stock_Tables

Note 8 - Common Stock (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Schedule of Conversions of Convertible Preferred Stock [Table Text Block]		2014		2013		2012
	Conversion of Series A Preferred Shares		202,857		2,048,570		1,882,667
	Conversion of Series B Preferred Shares		4,428,571		-0-		-0-
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Expiration Date	Number of Shares		Weighted Average
				Exercise Price
	31-Dec-16		1,806,159	$	1
	16-Jan-17		45,000		1
	31-Jan-17		567,001		1
	21-Mar-17		2,690,666		0.35
	Total Outstanding at December 31, 2014		5,108,826	$	0.66
Schedule of Stock by Class [Table Text Block]	Stock Purchase Warrants		5,108,826
	Stock Option Plan		1,197,529
	Series B Convertible Preferred Stock		285,715
	Total		6,592,070

Note_9_StockBased_Compensation1

Note 9 - Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Schedule of Share-based Compensation, Activity [Table Text Block]		Number			Weighted-			Weighted-			Aggregate
		of Shares			Average			Average			Intrinsic
					Exercise			Remaining			Value
					Price			Contractual
								Term (yrs)
	Outstanding at December 31, 2013		1,197,044		$	3.79
	Granted		217,500			0.17
	Exercised		-			-
	Forfeited or expired		(231,444	)		1.89
	Outstanding at December 31, 2014		1,183,100		$	3.5			6.6		$	-0-
	Exercisable at December 31, 2014		785,594		$	5.09			5.2		$	-0-
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]		2014			2013			2012
	Weighted average fair value of options granted	$	0.14		$	0.43		$	0.59
	Intrinsic value of options exercised		-0-			-0-			-0-
	Total fair value of options vested		97,707			165,490			319,920
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]		2014			2013			2012
	Weighted average risk-free interest rates		1.98	%		2.3	%		1.1	%
	Expected dividend yield		0	%		0	%		0	%
	Expected life of option (years)		7			7			6.7
	Expected volatility		94.88	%		96.6	%		105.2	%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]		2014			2013			2012
	General and administrative expense	$	69,057		$	101,896		$	231,936
	Research and development expense		32,134			41,539			78,140
	Total stock option expense	$	101,191		$	143,435		$	310,076

Note_11_Income_Taxes_Tables

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]		2014			2013
	Deferred tax assets:
	Net operating loss carryforward	$	22,831,626		$	21,983,109
	Research and development tax credit carryforward		825,896			799,248
	Stock-based compensation expense		2,396,805			2,233,909
	Total deferred tax assets		26,054,327			25,016,266
	Deferred tax liabilities
	Depreciation		(7,149	)		(13,386	)
	Total deferred tax liabilities		(7,149	)		(13,386	)
	Net deferred tax assets		26,047,178			25,002,881
	Valuation allowance		(26,047,178	)		(25,002,881	)
		$	-0-		$	-0-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		2014			2013			2012
	U.S. federal statutory rate applied to pretax loss	$	(929,409	)	$	(776,881	)	$	(725,948	)
	Permanent differences		1,734			3,138			2,674
	Research and development credits		26,648			14,047			21,236
	Change in valuation allowance		901,027			759,696			702,038
	Reported income tax expense	$	-0-		$	-0-		$	-0-

Note_13_Selected_Quarterly_Fin1

Note 13 - Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Schedule of Quarterly Financial Information [Table Text Block]		2014 Quarter Ended
		31-Mar			30-Jun			30-Sep			31-Dec
	Revenue from grants	$	157,340		$	180,441		$	322,086		$	223,089
	Net loss		(615,918	)		(679,537	)		(514,515	)		(923,585	)
	Net loss per share		(0.02	)		(0.03	)		(0.02	)		(0.03	)
		2013 Quarter Ended
		31-Mar			30-Jun			30-Sep			31-Dec
	Revenue from grants	$	797,040		$	441,561		$	1,004,211		$	174,738
	Net loss		(696,797	)		(526,284	)		(190,148	)		(871,714	)
	Net loss per share		(0.03	)		(0.02	)		(0.01	)		(0.04	)

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Tables
Summary of Valuation Allowance [Table Text Block]				Additions
	Description	Balance at		Charged to		Charged to		-1			Balance at
		Beginning		Costs and		Other		Deductions			End
		Of Period		Expenses		Accounts					Of Period
	Reserve Deducted in the Balance Sheet
	From the Asset to Which it Applies:
	Allowance for Deferred Tax Assets
	Year ended December 31, 2014	$	25,002,881	$	1,044,297	$	-0-	$	-0-		$	26,047,178
	Year ended December 31, 2013		27,295,741		862,736		-0-	$	(3,155,596	)		25,002,881
	Year ended December 31, 2012		27,591,230		817,472		-0-		(1,112,961	)		27,295,741

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6.6	14.4	13.3
Maximum [Member]
Accounting Policies [Abstract]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member]
Accounting Policies [Abstract]
Property, Plant and Equipment, Useful Life	3 years

Note_3_Property_and_Equipment_1

Note 3 - Property and Equipment (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Depreciation, Depletion and Amortization, Nonproduction	$59,037	$68,862	$73,720

Note_3_Property_and_Equipment_2

Note 3 - Property and Equipment - Property and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property and equipment, gross	$654,396	$618,892
Accumulated depreciation and amortization	-557,703	-498,665
Property and equipment, net	96,693	120,227
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Laboratory Equipment [Member]
Property and equipment, gross	510,106	474,602
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$28,685	$28,685

Note_4_Other_Assets_Details_Te

Note 4 - Other Assets (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Amortization of Intangible Assets	$10,000	$10,000	$19,923

Note_4_Other_Assets_Other_Asse

Note 4 - Other Assets - Other Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deposits	$11,010	$11,010
Total other assets	11,010	21,010
Patented Technology [Member]
Technology licenses	248,855	248,855
Accumulated amortization b technology licenses	($248,855)	($238,855)

Note_5_Government_Grants_Detai

Note 5 - Government Grants (Details Textual) (USD $)	3 Months Ended								12 Months Ended			1 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2007	Jul. 31, 2014	Jul. 31, 2013	Sep. 30, 2012
Revenue from Grants	$223,089	$322,086	$180,441	$157,340	$174,738	$1,004,211	$441,561	$797,040	$882,956	$2,417,550	$2,657,327
First N I H Grant [Member]
Revenue from Grants									624,689	833,390	2,227,924
Grant Award												20,400,000
Unused Grant Funds	75,464								75,464
NIH Grants [Member]
Revenue from Grants									882,956	2,417,550	2,657,327
SBIR Grant [Member]
Revenue from Grants									258,267	154,563	0
Grant Award													289,641	276,690
Unused Grant Funds	153,501								153,501
Second N I H Grant [Member]
Revenue from Grants									0	1,429,597	429,403
Grant Award															$1,900,000

Note_6_Commitments_Details_Tex

Note 6 - Commitments (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	sqft
Commitments and Contingencies Disclosure [Abstract]
Area of Real Estate Property	8,400
Operating Leases, Rent Expense	$117,084	$117,879	$118,801
Lessee Leasing Arrangements, Operating Leases, Term of Contract	5 years 60 days
Operating Leases, Future Minimum Payments Due, Next Twelve Months	146,092
Unrecorded Unconditional Purchase Obligation	$151,439

Note_7_Preferred_Stock_Details

Note 7 - Preferred Stock (Details Textual) (USD $)	1 Months Ended		12 Months Ended			1 Months Ended
In Millions, except Share data, unless otherwise specified	Jan. 31, 2014	Mar. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Preferred Stock, Shares Authorized			10,000,000	10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share			$0.01	$0.01		$0.01
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding			0	71		71
Preferred Stock, Shares Authorized		2,200
Preferred Stock, Par or Stated Value Per Share		$1,000	$1,000	$1,000		$1,000
Convertible Preferred Stock, Total Conversion Shares		2,933,333
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		8,799,999
Proceeds from Issuance of Convertible Preferred Stock		$2
Convertible Preferred Stock, Conversion Price Per Share		$0.75		$0.35		$0.35
Convertible preferred stock (in shares)	71		71	717	1,412
Common stock conversion (in shares)	202,857		202,857	2,048,570	1,882,667
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding			100	1,650		1,650
Preferred Stock, Par or Stated Value Per Share			$1,000	$1,000		$1,000
Convertible Preferred Stock, Total Conversion Shares			285,714	4,714,286		4,714,286
Proceeds from Issuance of Convertible Preferred Stock						1.6
Convertible Preferred Stock, Conversion Price Per Share			$0.35
Convertible preferred stock (in shares)			1,550
Common stock conversion (in shares)			4,428,571	0	0
Stock Issued During Period, Shares, New Issues						1,650
Gross Proceeds [Member] | Series A Convertible Preferred Stock [Member]
Proceeds from Issuance of Convertible Preferred Stock		2.2
Gross Proceeds [Member] | Series B Convertible Preferred Stock [Member]
Proceeds from Issuance of Convertible Preferred Stock						$1.65
Conversion Price Adjustment [Member] | Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding				788		788
Convertible Preferred Stock, Conversion Price Per Share				$0.35		$0.35

Note_7_Preferred_Stock_Allocat

Note 7 - Preferred Stock - Allocation of Net Proceeds from Preferred Stock Financing (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Initial carrying value of preferred stock	$76,095
Carrying value at December 31, 2014	76,095
Series A Convertible Preferred Stock [Member]
Fair value of warrants (recorded to Additional Paid-in Capital)	-1,127,418
Beneficial conversion feature (recorded to Additional Paid-in Capital)	-762,667
Net proceeds allocated to preferred stock	108,947
Accretion of beneficial conversion feature (deemed dividend)	762,667
Initial carrying value of preferred stock	0
Conversions to common stock	-1,231,843
Carrying value at December 31, 2014	0
Series A Convertible Preferred Stock [Member] | Gross Proceeds [Member]
Net proceeds	1,999,032
Series B Convertible Preferred Stock [Member]
Net proceeds allocated to preferred stock	501,283
Accretion of beneficial conversion feature (deemed dividend)	754,286
Initial carrying value of preferred stock	0
Conversions to common stock	-1,179,474
Carrying value at December 31, 2014	0
Series B Convertible Preferred Stock [Member] | Gross Proceeds [Member]
Net proceeds	1,615,798
Initial Carrying Value [Member] | Series A Convertible Preferred Stock [Member]
Initial carrying value of preferred stock	871,614
Carrying value at December 31, 2014	871,614
Series A Beneficial Conversion Feature [Member] | Series B Convertible Preferred Stock [Member]
Beneficial conversion feature (recorded to Additional Paid-in Capital)	-360,229
Series B Beneficial Conversion Feature [Member] | Series A Convertible Preferred Stock [Member]
Accretion of beneficial conversion feature (deemed dividend)	360,229
Series B Beneficial Conversion Feature [Member] | Series B Convertible Preferred Stock [Member]
Beneficial conversion feature (recorded to Additional Paid-in Capital)	($754,286)

Note_8_Common_Stock_Details_Te

Note 8 - Common Stock (Details Textual) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

2 Months Ended

1 Months Ended

5 Months Ended

Oct. 31, 2014

30-May-13

Jan. 17, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Oct. 31, 2013

Jan. 31, 2012

Sep. 30, 2014

Nov. 30, 2014

31-May-13

14-May-13

Apr. 30, 2013

Stockholders' Equity Note [Abstract]

Stock Issued During Period, Value, New Issues

$273,360

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.60

$0.66

$0.75

$0.50

$0.60

Proceeds from Warrant Exercises

873,400

583,333

1,060,000

Stock Issued During Period, Shares, Warrants Exercised

3,176,000

Class of Warrant or Right, Outstanding

2,933,333

5,108,826

Number Of Warrants Issued During Period

1,766,667

Class of Warrant or Right, Unissued

1,166,666

General and Administrative Expense

1,807,605

1,792,160

1,752,765

Warrant Exercise Fee Per Share

$0.08

Common Stock [Member]

Stockholders' Equity Note [Abstract]

Stock Issued During Period, Shares, New Issues

407,999

Stock Issued During Period, Value, New Issues

408

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,599,784

Class of Warrant or Right, Exercise Price of Warrants or Rights

$1

Stock Issued During Period, Shares, Issued for Services

378,205

50,000

50,000

Warrant [Member]

Stockholders' Equity Note [Abstract]

Other General and Administrative Expense

19,617

218,551

Members Of Board Of Directors And Management [Member]

Stockholders' Equity Note [Abstract]

Stock Issued During Period, Shares, New Issues

380,954

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

571,432

Class of Warrant or Right, Exercise Price of Warrants or Rights

$1

Members Of Board Of Directors And Management [Member] | Common Stock [Member]

Stockholders' Equity Note [Abstract]

Stock Issued During Period, Shares, New Issues

1,066,519

Stock Issued During Period, Value, New Issues

714,570

Expense Associated with Warrant Modifications [Member]

Stockholders' Equity Note [Abstract]

General and Administrative Expense

39,712

238,168

0

39,711

General and Administrative Expense [Member]

Stockholders' Equity Note [Abstract]

Allocated Share-based Compensation Expense

20,500

Third Party Consulting Services [Member]

Stockholders' Equity Note [Abstract]

Stock Issued During Period, Shares, Issued for Services

378,205

Allocated Share-based Compensation Expense

100,000

Common Stock Warrants [Member] | Common Stock [Member]

Stockholders' Equity Note [Abstract]

Stock Issued During Period, Shares, New Issues

2,933,333

Proceeds from Warrant Exercises

$1,643,333

Warrant Exercise Price Adjustment [Member]

Stockholders' Equity Note [Abstract]

Class of Warrant or Right, Outstanding

1,166,666

Warrants with Modified Exercise Prices [Member]

Stockholders' Equity Note [Abstract]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$1

Class of Warrant or Right, Outstanding

818,376

Warrants with Modified Exercise Prices [Member] | Scenario, Previously Reported [Member]

Stockholders' Equity Note [Abstract]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$16.50

Note_8_Common_Stock_Convertibl

Note 8 - Common Stock - Convertible Stock Issued (Details)	1 Months Ended	12 Months Ended
	Jan. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Series A Convertible Preferred Stock [Member]
Conversion of preferred stock (in shares)	202,857	202,857	2,048,570	1,882,667
Series B Convertible Preferred Stock [Member]
Conversion of preferred stock (in shares)		4,428,571	0	0

Note_8_Common_Stock_Outstandin

Note 8 - Common Stock - Outstanding Stock Purchase Warrants (Details) (USD $)	Dec. 31, 2014
Number of Shares (in shares)	5,108,826
Weighted Average Exercise Price (in dollars per share)	$0.66
Warrants Expiration 1[Member]
Number of Shares (in shares)	1,806,159
Weighted Average Exercise Price (in dollars per share)	$1
Warrants Expiration 2 [Member]
Number of Shares (in shares)	45,000
Weighted Average Exercise Price (in dollars per share)	$1
Warrants Expiration 3 [Member]
Number of Shares (in shares)	567,001
Weighted Average Exercise Price (in dollars per share)	$1
Warrants Expiration 4 [Member]
Number of Shares (in shares)	2,690,666
Weighted Average Exercise Price (in dollars per share)	$0.35

Note_8_Common_Stock_Common_Sto

Note 8 - Common Stock - Common Stock Reserved for Future Issuance (Details)	Dec. 31, 2014
Common Stock, Reserved for Future Issuance (in shares)	6,592,070
Employee Stock Option [Member]
Common Stock, Reserved for Future Issuance (in shares)	5,108,826
Warrant [Member]
Common Stock, Reserved for Future Issuance (in shares)	1,197,529
Series B Convertible Preferred Stock [Member]
Common Stock, Reserved for Future Issuance (in shares)	285,715

Note_9_StockBased_Compensation2

Note 9 - Stock-Based Compensation (Details Textual) (USD $)	12 Months Ended				1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2006	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
General and Administrative Expense	$1,807,605	$1,792,160	$1,752,765
2006 Equity Incentive Plan [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	110,235
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				1,200,000
Allocated Share-based Compensation Expense	101,191	143,435	310,076
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 328 days
Expense Associated with Warrant Modifications [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
General and Administrative Expense	39,712	238,168	0		39,711
Third Party Consulting Services [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Allocated Share-based Compensation Expense	100,000	20,500	0
Warrant Exercise Fee [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
General and Administrative Expense	238,200
Incentive Stock Options (ISO's) [Member] | 2006 Equity Incentive Plan [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent				110.00%
Non-employee Share-based Compensation [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$0

Note_9_StockBased_Compensation3

Note 9 - Stock-Based Compensation - Activity of Stock Option Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Number of shares (in shares)	1,183,100	1,197,044
Weighted average exercise price (in dollars per share)	$3.50	$3.79
Granted (in shares)	217,500
Granted (in dollars per share)	$0.17
Forfeited or expired (in shares)	-231,444
Forfeited or expired (in dollars per share)	$1.89
Weighted average remaining contractual period	6 years 219 days
Aggregate Intrinsic value	$0
Exercisable at December 31, 2014 (in shares)	785,594
Exercisable at December 31, 2014 (in dollars per share)	$5.09
Exercisable at December 31, 2014	5 years 73 days
Exercisable at December 31, 2014	$0

Note_9_StockBased_Compensation4

Note 9 - Stock-Based Compensation - Additional Information for Stock Options (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Weighted average fair value of options granted (in dollars per share)	$0.14	$0.43	$0.59
Total fair value of options vested	$97,707	$165,490	$319,920

Note_9_StockBased_Compensation5

Note 9 - Stock-Based Compensation - Significant Assumption Used in Fair Value Calculation (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Weighted average risk-free interest rates	1.98%	2.30%	1.10%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life of option (years)	7 years	7 years	6 years 255 days
Expected volatility	94.88%	96.60%	105.20%

Note_9_StockBased_Compensation6

Note 9 - Stock-Based Compensation - Allocation of Stock Option Expense (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Option [Member]
Allocated stock option expense	$101,191	$143,435	$310,076
Employee Stock Option [Member] | General and Administrative Expense [Member]
Allocated stock option expense	69,057	101,896	231,936
Employee Stock Option [Member] | Research and Development Expense [Member]
Allocated stock option expense	$32,134	$41,539	$78,140

Note_10_Retirement_Plan_Detail

Note 10 - Retirement Plan (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$35,567	$43,132	$50,500

Note_11_Income_Taxes_Details_T

Note 11 - Income Taxes (Details Textual) (USD $)	12 Months Ended			162 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$0	$0	$0	$0
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	64,600,000			64,600,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	$825,896	$799,248		$825,896

Note_11_Income_Taxes_Deferred_

Note 11 - Income Taxes - Deferred Tax Assets and Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforward	$22,831,626	$21,983,109
Research and development tax credit carryforward	825,896	799,248
Stock-based compensation expense	2,396,805	2,233,909
Total deferred tax assets	26,054,327	25,016,266
Deferred tax liabilities
Depreciation	-7,149	-13,386
Total deferred tax liabilities	-7,149	-13,386
Net deferred tax assets	26,047,178	25,002,881
Valuation allowance	-26,047,178	-25,002,881
	$0	$0

Note_11_Income_Taxes_Reconcili

Note 11 - Income Taxes - Reconciliation of Income Tax Benefit (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
U.S. federal statutory rate applied to pretax loss	($929,409)	($776,881)	($725,948)
Permanent differences	1,734	3,138	2,674
Research and development credits	26,648	14,047	21,236
Change in valuation allowance	901,027	759,696	702,038
Reported income tax expense	$0	$0	$0

Note_12_Related_Party_Transact1

Note 12 - Related Party Transactions (Details Textual) (USD $)	12 Months Ended			2 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2012	14-May-13	Apr. 30, 2013	Jan. 17, 2013
Related Party Transactions [Abstract]
Proceeds from Issuance of Common Stock	$873,400	$1,643,333	$310,160
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.66		$0.75		$0.50	$0.60	$0.60
Members Of Board Of Directors And Management [Member]
Related Party Transactions [Abstract]
Stock Issued During Period, Shares, New Issues				380,954
Proceeds from Issuance of Common Stock				255,239
Class Of Warrant Or Right Purchase Period				5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				571,432
Class of Warrant or Right, Exercise Price of Warrants or Rights				$1
Ongoing Patent Cost Reimbursements [Member] | Emory [Member]
Related Party Transactions [Abstract]
Related Party Transaction, Expenses from Transactions with Related Party	179,958	98,042	89,885
Research Agreements [Member] | Emory [Member]
Related Party Transactions [Abstract]
Related Party Transaction, Expenses from Transactions with Related Party	$0	$252,478	$552,403

Note_13_Selected_Quarterly_Fin2

Note 13 - Selected Quarterly Financial Data (unaudited) - Selected Quarterly Financial Data (Details) (USD $)	3 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
Grant revenue	$223,089	$322,086	$180,441	$157,340	$174,738	$1,004,211	$441,561	$797,040
Net loss	($923,585)	($514,515)	($679,537)	($615,918)	($871,714)	($190,148)	($526,284)	($696,797)
Net loss per share (in dollars per share)	($0.03)	($0.02)	($0.03)	($0.02)	($0.04)	($0.01)	($0.02)	($0.03)

Note_14_Subsequent_Event_Detai

Note 14 - Subsequent Event (Details Textual) (USD $)	1 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 27, 2015	Dec. 31, 2014	14-May-13	Apr. 30, 2013	Jan. 17, 2013	Dec. 31, 2012
Subsequent Events [Abstract]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.66	$0.50	$0.60	$0.60	$0.75
Series C Convertible Preferred Stock [Member] | Subsequent Event [Member]
Subsequent Events [Abstract]
Proceeds from Issuance of Convertible Preferred Stock	$3
Convertible Preferred Stock, Conversion Price Per Share	$0.18
Convertible Preferred Stock, Total Conversion Shares	16,666,666
Series D Warrants [Member] | Subsequent Event [Member]
Subsequent Events [Abstract]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	16,666,666
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.22
Series D Warrants [Member] | Placement Agent for Offering [Member] | Subsequent Event [Member]
Subsequent Events [Abstract]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,333,333
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.22
Series E Warrants [Member] | Subsequent Event [Member]
Subsequent Events [Abstract]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	16,666,666
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.18
Series F Warrants [Members] | Subsequent Event [Member]
Subsequent Events [Abstract]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	16,666,666
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.22

Schedule_II_Valuation_and_Qual2

Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details) (Valuation Allowance of Deferred Tax Assets [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Valuation Allowance of Deferred Tax Assets [Member]
Balance at Beginning Of Period	$25,002,881	$27,295,741	$27,591,230
Additions Charged to Costs and Expenses	1,044,297	862,736	817,472
Additions Charged to Other Accounts	0	0	0
Deductions	0	-3,155,596	-1,112,961
Balance at End Of Period	$26,047,178	$25,002,881	$27,295,741